Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Arcturus Therapeutics Inc. manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 7 distinct examiners, ensuring that each active case is under the review of a different individual. This diversity in examiners suggests that the company's prosecution strategy must be highly adaptable to various personal examination styles. Managing the distinct examiners requires significant coordination to maintain consistency across the portfolio.
The pending office actions are spread across 5 distinct art units, which is a relatively high number of units for the volume of actions. This indicates that the portfolio covers a wide range of technical sub-specialties within the Biotechnology & Pharmaceuticals field. TCHERKASSKAYA, OLGA V is the busiest examiner with 1 pending office action, reflecting an even distribution of work where no single examiner dominates the current pending workload. The presence of 5 distinct art units suggests a broad research and development focus.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| CRUM, MARY ABOU NADER | 1 | 40.4% | +65.0% |
| SCHACHERMEYER, SAMANTHA LYNN | 1 | 36.8% | +72.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18660219 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | SHOMER, ISAAC | — |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18984131 | METHOD OF LYOPHILIZING LIPID NANOPARTICLES | TCHERKASSKAYA, OLGA V | — |
| 18660219 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | SHOMER, ISAAC | — |
| 18614077 | LIPID NANOPARTICLES ENCAPSULATION OF LARGE RNA | SASAN, ARADHANA | — |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | ALLEN, MICHAEL D | — |
| 18345379 | METHODS FOR IN VITRO TRANSCRIPTION | MEYERING, SHABANA SHABBEER | — |
| 17737884 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | CRUM, MARY ABOU NADER | — |
| 17619882 | IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM | SCHACHERMEYER, SAMANTHA LYNN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1671 | 1 |
| 1635 | 1 |
| 1657 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18984131 | METHOD OF LYOPHILIZING LIPID NANOPARTICLES | TCHERKASSKAYA, OLGA V | — | §112 | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18660219 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | SHOMER, ISAAC | — | §102§103§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18614077 | LIPID NANOPARTICLES ENCAPSULATION OF LARGE RNA | SASAN, ARADHANA | 1615 | DP | Final Rejection | — | Pending | Mar 22, 2024 |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | ALLEN, MICHAEL D | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18345379 | METHODS FOR IN VITRO TRANSCRIPTION | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | — | Pending | Jun 30, 2023 |
| 17737884 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | CRUM, MARY ABOU NADER | 1657 | §102§103§112DP | Non-Final OA | — | Pending | May 05, 2022 |
| 17619882 | IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Non-Final OA | — | Pending | Dec 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial